| Code | CSB-RA011087MB5HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar of teprotumumab N01 (SYCUME®/IBI-311), targeting IGF1R (insulin-like growth factor 1 receptor)—a transmembrane receptor tyrosine kinase that propagates growth-factor signals through canonical pathways including PI3K–AKT and RAS–MAPK. In thyroid eye disease (TED), IGF1R is reported to be overexpressed on orbital fibroblasts (and on immune cells such as T and B cells), and IGF1R can form a functional complex with the TSH receptor (TSHR), linking receptor crosstalk to fibroblast activation and tissue remodeling.
Teprotumumab is a fully human IGF1R-blocking monoclonal antibody developed to inhibit IGF1R activation and downstream signaling in TED. Mechanistic studies in TED orbital fibroblasts have shown that teprotumumab can suppress hyaluronan production by inhibiting TSHR/IGF1R crosstalk, supporting its use as a tool to dissect pathway-level drivers of orbital inflammation and extracellular matrix expansion. This biosimilar provides the antibody component alone, enabling researchers to investigate IGF1R biology, receptor engagement and signaling modulation, and TED-relevant cellular phenotypes (e.g., orbital fibroblast activation) in controlled experimental systems.
There are currently no reviews for this product.